Rethinking the INN system for therapeutic antibodies

  title={Rethinking the INN system for therapeutic antibodies},
  author={J{\'e}r{\'e}my Pottier and Romane Chastang and Christophe Dumet and H. Watier},
  pages={5 - 11}
  • Jérémy Pottier, Romane Chastang, +1 author H. Watier
  • Published 2017
  • Medicine
  • mAbs
  • ABSTRACT In the context of a possible revision of the International Nonproprietary Names (INN) system of recombinant monoclonal antibodies, which is saturated, we propose several avenues of reflection driven by the primary goal of the INN, information of health-care professionals. Clinical considerations argue for an abandon of the substems A (target category) and B (origin category), which lengthen the INN without real added-value. On the contrary, new substems or suffixes are required to… CONTINUE READING
    9 Citations
    Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives
    • 5
    • PDF
    Obinutuzumab: what is there to learn from clinical trials?
    • 36
    • PDF
    [Which immunoglobulin heavy chains for which immunostimulatory antibodies?]
    MABp1 for the treatment of colorectal cancer
    • 6
    Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
    • 54
    • Highly Influenced
    • PDF


    The INNs and outs of antibody nonproprietary names
    • 33
    • PDF
    Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
    • 126
    • PDF
    Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.
    • 57
    • PDF
    Human immunoglobulin allotypes
    • 152
    Immunogenicity of therapeutic proteins: Influence of aggregation
    • 283
    International Nonproprietary Names (INN) for pharmaceutical substances.
    • S. Kopp-Kubel
    • Medicine
    • Bulletin of the World Health Organization
    • 1995
    • 61
    • PDF
    IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding
    • 42
    • PDF
    Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.
    • 409
    • PDF
    Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions
    • 27
    • PDF
    IgG Subclasses and Allotypes: From Structure to Effector Functions
    • 971
    • PDF